Thoracic Cancer (Feb 2024)

Relationship between patterns of immunohistochemical conventional neuroendocrine markers and efficacy of immune check point inhibitors in patients with extensive disease small cell lung cancer

  • Yuko Iida,
  • Kazushige Wakuda,
  • Takuya Kawata,
  • Meiko Morita,
  • Motoki Sekikawa,
  • Kosei Doshita,
  • Michitoshi Yabe,
  • Hiroaki Kodama,
  • Keita Miura,
  • Noboru Morikawa,
  • Nobuaki Mamesaya,
  • Haruki Kobayashi,
  • Ryo Ko,
  • Akira Ono,
  • Hirotsugu Kenmotsu,
  • Tateaki Naito,
  • Haruyasu Murakami,
  • Yasuhiro Gon,
  • Toshiaki Takahashi

DOI
https://doi.org/10.1111/1759-7714.15218
Journal volume & issue
Vol. 15, no. 6
pp. 477 – 485

Abstract

Read online

Abstract Background Which patients benefit from the addition of immune checkpoint inhibitors (ICIs) to chemotherapy for small cell lung cancer (SCLC) remains unclear. There have been few reports on the efficacy of ICIs based on conventional immunohistochemical neuroendocrine (NE) markers (synaptophysin, chromogranin A, and neural cell adhesion molecule [NCAM]). In the present study, we aimed to analyze the relationship between the expression of immunohistochemical NE markers and the efficacy of ICIs in patients with extensive disease (ED)‐SCLC, to assess whether conventional NE markers are predictive of ICIs. Methods Patients with untreated ED‐SCLC who received first‐line therapy at the Shizuoka Cancer Center between November 2002 and July 2021 were retrospectively reviewed. We evaluated the efficacy of first‐line chemotherapy according to the expression status of each immunohistochemical NE marker in patients treated with ICI plus chemotherapy (ICI‐chemo group) and with chemotherapy alone (chemo group). Results A total of 227 patients were included in the ICI‐chemo and chemo groups, respectively. The progression‐free survival (PFS) tended to be better in patients in the ICI‐chemo group than those treated with chemotherapy alone in patients with NE marker‐positive SCLC. In particular, it was statistically significant in patients with chromogranin A‐positive SCLC (p = 0.036). In patients with NE marker‐negative SCLC, no significant differences were observed in PFS between the two groups. There were no significant differences in overall survival (OS), regardless of the expression of any conventional NE marker. Conclusion Our study suggests that the efficacy of ICIs in addition to chemotherapy may be poor in patients with NE marker‐negative SCLC.

Keywords